our technology

alphalex™ is a tumor targeting platform.

Cybrexa alphalex powers new applications and combinations of existing cancer therapeutics using an elegant approach for targeted intracellular drug delivery, independent of surface antigens. Leveraging alphalex, we are passionate about discovering new ways to effectively treat cancer and meaningfully improve lives.

What

alphalex forges the way towards synergistic combination therapies that were previously limited by toxicity, opening the door for new indications and providing hope for patients with few or no treatment options.

How

By using technology that allows small molecule anti-cancer agents to penetrate cell membranes only at low pH, alphalex leverages the acidic tumor microenvironment to selectively release drug molecules directly within tumor cells while limiting toxicity to healthy tissue. alphalex contains a pHLIP®peptide. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc.

Why

We strive to expand the boundaries of cancer therapeutics, enabling more treatment options and paving paths forward for more patients.

Partner with Us

how alphalex selectively targets tumor cells

watch video

With straightforward mechanism of action, alphalex provides an elegant approach to tumor-targeted anti-cancer agents.

new therapeutic opportunities

As a tumor selective platform, alphalex can enable new therapeutic uses across different classes of small molecules, unlocking new and better cancer therapeutics and bringing new options to patients.

Focus: Toxin Conjugates

We’re expanding the population of treatable patients through novel toxin conjugates.

See What’s in Our Pipeline

contact us

We’d love to hear from you